Effect of ustekinumab on extraintestinal manifestations in patients with Crohn’s disease or ulcerative colitis-Reference-Cited by-同舟云学术

Effect of ustekinumab on extraintestinal manifestations in patients with Crohn’s disease or ulcerative colitis

Published:2024-06-10 Issue:8 Volume: Page:135-142
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Abdulganieva D. I.¹^ORCID,Mukhametova D. D.¹^ORCID

Affiliation:

1. Kazan State Medical University

Abstract

This review presents the main extraintestinal manifestations (EIMs) in patients with inflammatory bowel diseases (IBD), in particular ulcerative colitis (UC) and Crohn’s disease (CD), describes the modern potential mechanisms, classification, characteristics and frequency of the main EIMs (rheumatological, skin, ophthalmological and orofacial manifestations). The issues of the mechanism of action, indications for prescribing ustekinumab are also covered in detail, the place of ustekinumab in the treatment of IBD is highlighted, the effectiveness of this drug in relation to the treatment of IBD is assessed – summarizes the results of a retrospective analysis of data from the UNITI-1, UNITI-2, IM-UNITI clinical trial program, prospective cohort studies, retrospective cohort studies and a registry study on the effect of ustekinumab on the course of various EIMs and the outcomes of immune-mediated diseases (IMDs) in patients with CD and UC. Ustekinumab is a fully monoclonal human immunoglobulin G1k that binds to the common p40 subunit of interleukin (IL)-12 and IL-23, which are actively involved not only in the development of intestinal symptoms, but are also triggers in the development of various EIMs. A review of the literature showed that ustekinumab may be effective for the treatment of EIMs in patients with UC and CD, especially in relation to dermatological and rheumatological manifestations, and is effective against psoriasis and psoriatic arthritis. A literature search of MEDLINE®, EMBASE®, BIOSIS Previews® and DERWENT® and/or other resources, including internal/external databases was conducted on April 15, 2024.

Publisher

Remedium, Ltd.

Reference29 articles.

1. Maev IV, Bakulin IG, Skalinskaya MI, Skazyvaeva EV. Inflammatory bowel diseases: Transformation of representations. A review. Terapevticheskii Arkhiv. 2023;95(12):1064–1074. (In Russ.) https://doi.org/10.26442/00403660. 2023.12.202507.

2. Shelygin YA, Ivashkin VT, Belousova EA, Reshetov IV, Maev IV, Achkasov SI et al. Ulcerative colitis (К51), adults. Koloproktologia. 2023;22(1):10–44. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-1-10-44.

3. Shelygin YA, Ivashkin VT, Achkasov SI, Reshetov IV, Maev IV, Belousova EA et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10–49. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-3-10-49.

4. Belousova EA, Shelygin YuA, Achkasov SI, Khatkov IE, Bakulin IG, Skalinskaya MI et al. Clinical and demographic features and treatment approaches for inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in the Russia. The primery results of the analysis of the National Register. Koloproktologia. 2023;22(1):65–82. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-1-65-82.

5. Belousova EA, Abdulganieva DI, Alexeeva OP, Alexeenko SA, Baranovsky AYu, Valuyskikh EYu et al. Social and demographic characteristics, features of disease course and treatment options of inflammatory bower disease in Russia: Results of two multicenter studies. Almanac of Clinical Medicine. 2018;46(5):445–463 (In Russ.) https://doi.org/10.18786/2072-0505-2018- 46-5-445-463.